What is claimed is:
1. A cup holding device for a vehicle, comprising:
a base member having front and lower portions, an opening formed at the front portion, and a first receiving portion formed at a front lower portion,
a lid member pivotally supported at the lower portion of the base member and having a second receiving portion, said lid member rotatably shifted between a closed position where the lid member covers the base member and an open position in a using state where the lid member is tilted with respect to the base member, and
a holding member for holding a periphery of a container, said holding member being assembled between the base member and the lid member to be shifted between a vertical state at the closed position of the lid member and a horizontal using state at the open position of the lid member so that said first and second receiving portions of the base member and the lid member are positioned substantially at a same level at the open position of the lid member to jointly receive thereon a bottom portion of the container.
2. A cup holding device according to claim 1, wherein said base member includes a notched portion at an upper portion thereof for partly receiving the cup therein, said first receiving portion being located under the notched portion.
3. A cup holding device according to claim 2, wherein said base member is substantially vertically disposed with respect to a portion to be attached.
4. A cup holding device according to claim 2, wherein said second receiving portion is located above the first receiving portion when the lid member is in the closed position.
5. A cup holding device according to claim 2, wherein said holding member includes a frame portion having two ends slidably connected to the base member and a semicircular inner portion between the two ends for holding the container together with the notched portion; and an arm portion fixed to the frame portion and rotatably attached to the lid member.
6. A cup holding device according to claim 1, further comprising an urging member disposed between the base member and the lid member to urge the lid member from the closed position to the open position and vice versa by shifting an operation direction according to a rotation angle of the lid member.
7. A cup holding device for a vehicle, comprising:
a base member having front, upper and lower portions, an opening formed at the front portion, and a first holding portion formed at a front upper portion,
a lid member pivotally supported at the lower portion of the base member to be rotatably shifted between a closed position where the lid member covers the base member and an open position in a using state where the lid member is tilted with respect to the base member, and
a holding member for holding a periphery of a container assembled between the base member and the lid member to be shifted between a vertical state at the closed position of the lid member and a horizontal using state at the open position of the lid member, said holding member having a second holding portion with a semi-circular arc shape so that a periphery of the container is jointly supported by the first and second holding portions.
8. A cup holding device according to claim 7, wherein said holding member includes a frame portion having the semi-circuit arc shape to constitute said second holding portion and an arm portion projecting forward from an intermediate position of the frame at the open position of the lid member; said base member includes vertical guiding grooves on two sides thereof, two ends of said frame being fitted in the vertical guiding grooves of the base member; and said arm portion is rotatably supported at one side of the lid member.
9. A cup holding device according to claim 7, further comprising an urging member disposed between the base member and the lid member to urge the lid member from the closed position to the open position and vice versa by shifting an operation direction according to a rotation angle of the lid member.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound according to formula I:
wherein:
A) R1 is -L1-C(R6aR6b)mR7, wherein:
a) L1 is selected from the group consisting of covalent bond, \u2014O\u2014, \u2014S\u2014, \u2014N\u2014, \u2014CO2\u2014, \u2014CO\u2014, \u2014OCO2\u2014, \u2014SO\u2014, \u2014SO2\u2014, \u2014CSN(R8)\u2014, \u2014CON(R8)O\u2014, \u2014CON(R8)\u2014, \u2014OCON(R8)\u2014; wherein R8 is hydrogen or substituted or unsubstituted C1-C5 alkyl;
b) R6a and R6b are each independently selected from the group consisting of hydrogen, \u2014OR9, \u2014N(R9)2, \u2014CO2R9, \u2014CON(R9)2, \u2014NHCOR9, \u2014NHCO2R9, \u2550NR9, \u2014R9, and mixtures thereof; wherein each R9 is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C5 alkyl, and substituted or unsubstituted aryl or alkylenearyl; or two R9 units can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;
c) m is an index selected from 0 to 5;
d) R is selected from the group consisting of nil, hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C1-C10 heteroalkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; or
e) R7 and a R9 can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;
B) R2 is \u2014(CH2)j-L2-C(R11aR11b)gR12, wherein:
a) j is an index selected from 0 to 5;
b) L2 is selected from the group consisting of covalent bond, \u2014O\u2014, \u2014S\u2014, \u2014N\u2014, \u2014CO2\u2014, \u2014CO\u2014, \u2014OCO2\u2014, \u2014SO\u2014, \u2014SO2\u2014, \u2014CSN(R10)\u2014, \u2014CON(R10)\u2014, \u2014CON(R10)O\u2014, \u2014OCON(R10)\u2014; wherein R10 is hydrogen or substituted or unsubstituted C1-C5 alkyl;
c) R11a and R11b are each independently selected from the group consisting of hydrogen, \u2014OR13, \u2014N(R13)2, \u2014CO2R13, \u2014CON(R13)2, \u2014NHCOR13, \u2014NHCO2R13, \u2550NR13, \u2014R13, and mixtures thereof; wherein each R13 is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C5 alkyl, and substituted or unsubstituted aryl or alkylenearyl; or two R13 units can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;
d) g is an index selected from 0 to 5;
e) R12 is selected from the group consisting of nil, hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; or
f) R12 and a R13 can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; and
C) R4 and R5 are each independently selected from hydrogen or substitution unit.
2. The compound of claim 1 having the formula (II):
3. The compound of claim 2, wherein:
a) j is 0; and
b) L2 is \u2014CON(R8)\u2014; and
c) R6a and R6b are each hydrogen.
4. The compound of claim 3, wherein L1 is selected from the group consisting of \u2014CO\u2014, \u2014CO2\u2014, and SO2\u2014.
5. The compound of claim 4, wherein R7 is substituted or unsubstituted phenyl.
6. The compound of claim 2, wherein L1 is selected from \u2014CO\u2014, \u2014CO2\u2014, \u2014CONH\u2014, and \u2014SO2\u2014.
7. The compound of claim 6, wherein R2 is hydrogen.
8. The compound of claim 2, wherein
a) R2 is hydrogen; and
b) L1 is \u2014CO\u2014
9. The compound of claim 8, wherein:
a) R6a and R6b are each hydrogen; and
b) m is an index from 1-5.
10. The compound of claim 9, wherein R7 substituted or unsubstituted phenyl.
11. The compound of claim 2, wherein:
a) j is o; and
b) L2 is \u2014CON(R8)\u2014.
12. The compound of claim 11, wherein:
a) L1 is selected from \u2014CO\u2014, and \u2014CO2\u2014; and
b) R7 is substituted or unsubstited C1-C10 alkyl.
13. The compound of claim 2, wherein:
a) L1 is \u2014CO2\u2014; and
b) R7 is substituted or unsubstituted C1-C10 alkyl.
14. The compound of claim 13, wherein:
a) j is 0; and
b) L2 is selected from covalent bond, \u2014CO2\u2014, and \u2014CON(CH3)O\u2014
15. The compound of claim 14, wherein R12 is selected from substituted or unsubstituted C1-C10 alkyl.
16. The compound of claim 1, wherein the compound is selected from the group consisting of:
(S)-3-Methylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; (S)-3-Methylcarbamoyl-2-(3-phenyl-propionyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-2-Benzylcarbamoyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-(3-Methylcarbamoyl-2-phenylmethanesulfonyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-sulfamic acid; (S)-{3-Methylcarbamoyl-2-3-(4-trifluoromethyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-3-Methylcarbamoyl-2-(4-phenyl-butyryl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-3-Methylcarbamoyl-2-(5-phenyl-pentanoyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-{3-Methylcarbamoyl-2-3-(3-sulfoamino-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-3-Methylcarbamoyl-2-(3-p-tolyl-propionyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-{2-3-(3-Hydroxy-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-{2-3-(4-Methoxy-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-3-Benzylcarbamoyl-2-(4-propyl-benzoyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-3-Benzylcarbamoyl-2-(3-phenyl-propionyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; (S)-3-Benzylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester; (S)-{3-Methylcarbamoyl-2-3-(3-sulfamoyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-{2-3-(3-Acetylsulfamoyl-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-{3-Methylcarbamoyl-2-3-(3-propionylsulfamoyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-(2-{3-3-(2,2-Dimethyl-propionylsulfamoyl)-phenyl-propionyl}-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-sulfamic acid; (S)-{2-3-(3-Benzoylsulfamoyl-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-{3-Methylcarbamoyl-2-3-(4-sulfamoyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-{2-3-(4-Acetylsulfamoyl-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (R)-{3-Methylcarbamoyl-2-3-(3-sulfamoyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (R)-{2-3-(3-Acetylsulfamoyl-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}sulfamic acid; (S)-3-3-(3-Methylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinolin-2-yl)-3-oxo-propyl-benzoic acid; (S)-{2-3-(3-Acetylsulfamoyl-phenyl)-propionyl-3-phenethylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-(2-Benzoyl-3-methylcarbamoyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-sulfamic acid; (S)-{2-3-(3-Chloro-phenyl)-propionyl-3-methylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; 7-Sufoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; 7-Sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester; 2-(Benzylcarbamoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-sulfamic acid; 2-(3-Phenyl-propionyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl-sulfamic acid; {2-2-(1-methyl-1H-indol-3-yl)-acetyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; 2-(Phenylmethanesulfonyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-sulfamic acid; 4-Oxo-4(7-sulfoamino-3,4-dihydro-1H-isoquinolin-2-yl)-butyric acid; {2-3-(3-Sulfoamino-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; {2-3-(3-Acetylsulfamoyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; {2-3-(3-Sulfamoyl-phenyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; (S)-4-(3-Methylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinolin-2-yl)4-oxo-butyric acid; (S)-3-Phenethylcarbamoyl-7-sulfoamino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid tert-butyl ester; (S)-3-Ethylcarbamoyl-7-sulfoamino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid tert-butyl ester; (S)-(3-Benzylcarbamoyl-2-hexanoyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-sulfamic acid; (S)-3-Benzylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; (R)-7-Nitro-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid; (S)-3-Methylcarbamoyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; (S)-7-Nitro-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid-2-tert-butyl ester-3-methyl ester; (S)-3-Hydroxymethyl-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; (S)-3-(Methoxy-methyl-carbamoyl)-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; (S)-3-(Methoxy-methyl-carbamoyl)-7-sulfoamino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester; (S)-7-Sulfoamino-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-tert-butyl ester 3-isobutyl ester; {3-Methylcarbamoyl-2-3-(naphthalene-1-sulfonyl)-propionyl-1,2,3,4-tetrahydro-isoquinolin-7-yl}-sulfamic acid; and R-1-Carbamoylmethyl-2-oxo-2(7-sulfoamino-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl-carbamic acid tert butyl ester.
17. A method of treating a protein tyrosine phosphatase (PTPase) mediated disorder comprising administering a compound of claim 1 to a subject in need thereof.
18. The method of claim 17, wherein the disorder is selected from the group consisting of atherosclerotic cardiovascular disease including peripheral vascular disease, coronary disease and cerebral vascular disease; heart failure; hypertension; diabetes (Type 1 and Type 2); skeletal muscle atrophy; osteoporosis; obesity; disorders of the gastrointestinal tract including inflammatory bowel disease and ulcer; wound healing and wrinkle repairprevention; hair loss and cancer.
19. A pharmaceutical composition comprising:
a) safe and effective amount of a compound of claim 1;
b) a pharmaceutically-acceptable carrier.